Sana Biotechnology Inc. has outlined the status of its pipeline following a portfolio prioritization. The company remains on track to file an IND this year for SC-291, the company's HIP-modified, CD19-targeted allogeneic chimeric antigen receptor (CAR) T therapy, with initial clinical data expected next year.
Eterna Therapeutics Inc. has entered into a sponsored research agreement with a collaborator at The University of Texas MD Anderson Cancer Center (MD Anderson).
Fibroblasts expressing the tumor suppressor p16INK4a (a marker of senescence) stimulated lung stem cells from young mice to repair damaged tissue, according to a study from the University of California, San Francisco (UCSF). The finding calls into question therapies that eliminate these senescent cells without considering their beneficial role in tissue homeostasis.
Therapeutic Solutions International Inc. has announced promising data on the use of Campbellcell for treatment of bipolar disorder by the company's suicide prevention-based spin-off Campbell Neurosciences Inc.
Stemcyte Inc. has received IND approval from the FDA for a phase II trial using umbilical cord blood stem cell therapy for post-COVID syndrome, or long COVID.
Research over the past decade has shown embryonic stem cells can undergo many disparate aspects of mammalian embryogenesis in vitro. But without the support of extra-embryonic stem cells that go on to form the placenta and yolk sac, development stalls. Now, two groups of researchers, led by scientists at the Weizmann Institute in Israel and Cambridge University, U.K., have taken the in vitro development of whole mouse embryos further, by adding or inducing the differentiation of trophoblast cells and extra-embryonic endoderm stem cells.
Using long-term in vivo imaging combined with computational modeling, a multinational team of researchers has gained new insights into what makes potential stem cells able to fulfill their role functionally.
Two studies published back to back in Nature have looked at the accumulation of mutations in blood-forming stem cells with age, gaining new insights into how the overall landscape of such cells changes across the lifespan.
Mica Biosystems Ltd. is linking up with U.K. innovation center Cell and Gene Therapy Catapult (CGT Catapult) to accelerate commercialization of its regenerative technology platform. CGT Catapult is supporting the Birmingham, U.K.-based startup as it engages in conversations with the U.K.’s Medicines and Healthcare Products Regulatory Agency for clinical trials testing its remote-controlled stem cell therapy platform.
Japanese researchers have created complex 3D kidney organoids that could lead the way to better kidney research and even artificial kidneys for human transplant.
RSS
